DynaGen Inc. has received its first product marketing approvalfrom the FDA, for urine test strips that determine whetherpatients are taking their anti-tuberculosis medicine.

Isoniazid treatment for tuberculosis, which is becoming morewidespread in the United States, requires daily doses for up toa year. Skipping pills can cause the microbe to become drug-resistant.

The Cambridge, Mass., company (NASDAQ:DYGN) will marketthe strips worldwide through direct sales and distributors.

(c) 1997 American Health Consultants. All rights reserved.